View ValuationImexpharm 将来の成長Future 基準チェック /16Imexpharmは、17.2%と10.4%でそれぞれ年率17.2%で利益と収益が成長すると予測される一方、EPSはgrowで11.8%年率。主要情報17.2%収益成長率11.83%EPS成長率Pharmaceuticals 収益成長16.1%収益成長率10.4%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日09 Jun 2026今後の成長に関する最新情報Price Target Changed • Aug 23Price target increased by 9.2% to ₫78,485Up from ₫71,861, the current price target is an average from 3 analysts. New target price is 8.1% below last closing price of ₫85,400. Stock is up 46% over the past year. The company is forecast to post earnings per share of ₫4,012 for next year compared to ₫3,307 last year.Price Target Changed • Aug 17Price target increased by 14% to ₫84,000Up from ₫73,633, the current price target is provided by 1 analyst. New target price is 20% above last closing price of ₫69,800. Stock is up 10% over the past year. The company is forecast to post earnings per share of ₫4,858 for next year compared to ₫2,951 last year.Price Target Changed • Jan 04Price target decreased to ₫66,600Down from ₫73,633, the current price target is an average from 2 analysts. New target price is 11% above last closing price of ₫60,200. Stock is down 21% over the past year. The company is forecast to post earnings per share of ₫3,444 for next year compared to ₫2,600 last year.Price Target Changed • Jul 14Price target increased to ₫79,000Up from ₫73,633, the current price target is an average from 2 analysts. New target price is 27% above last closing price of ₫62,000. Stock is down 15% over the past year. The company is forecast to post earnings per share of ₫3,069 for next year compared to ₫2,600 last year.Price Target Changed • Aug 10Price target increased to ₫75,300Up from ₫68,400, the current price target is an average from 3 analysts. New target price is 5.5% above last closing price of ₫71,400. Stock is up 63% over the past year.Price Target Changed • Dec 23Price target raised to ₫57,910Up from ₫52,663, the current price target is an average from 2 analysts. The new target price is close to the current share price of ₫56,000. As of last close, the stock is up 49% over the past year.すべての更新を表示Recent updatesUpcoming Dividend • Jul 06Upcoming dividend of ₫600 per shareEligible shareholders must have bought the stock before 13 July 2026. Payment date: 21 July 2026. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Vietnamese dividend payers (8.1%). Lower than average of industry peers (3.7%).お知らせ • Jul 03Imexpharm Corporation Announces Cash Dividend for the Year 2025, Payable on July 21, 2026Imexpharm Corporation announced the cash dividend of 6% per share VND 600 for each share for the year 2025, payable on July 21, 2026. Record date is on July 14, 2026.お知らせ • Apr 30Livzon Pharmaceutical Group Inc. (SZSE:000513) acquired 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion.Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 77.94% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6.9 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. On December 29, 2025, the parties signed Amendment Agreement to Framework Agreement agreeing to increase the maximum number of shares to be acquired through this proposed public tender offer to 120,059,970 shares, 77.94% stake, in accordance with Imexpharm Corporation’s foreign ownership cap requirements, and the Company will pay a maximum of VND 6,891,442,278,000. As of March 6, 2026 Livzon Pharmaceutical Group has officially received approval from the State Securities Commission of Vietnam. This allows them to proceed with a voluntary public tender offer for IMP shares. The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The number of shares intended to be sold by the Target Company’s shareholders does not reach the minimum threshold of 99,839,990 shares, representing 64.81% of the Target Company’s charter capital. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement. The transaction has been approved by the board of directors of Livzon Pharmaceutical Group Inc. Ernst & Young Vietnam Limited acted as due diligence provider to SK Investment Vina III Pte Ltd. Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion on April 29, 2026. Shareholders of Livzon Pharmaceutical Group Inc. have reached the minimum threshold of 99,839,990 shares, representing 64.81% of Imexpharm Corporation.Reported Earnings • Mar 28Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: EPS: ₫1,976 (up from ₫1,791 in FY 2024). Revenue: ₫2.44t (up 11% from FY 2024). Net income: ₫304.4b (up 10% from FY 2024). Profit margin: 13% (in line with FY 2024). Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 09Imexpharm Corporation, Annual General Meeting, Apr 22, 2026Imexpharm Corporation, Annual General Meeting, Apr 22, 2026.Reported Earnings • Jan 22Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: EPS: ₫1,976 (up from ₫1,932 in FY 2024). Revenue: ₫2.44t (up 11% from FY 2024). Net income: ₫304.4b (up 2.3% from FY 2024). Profit margin: 13% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Oct 23Third quarter 2025 earnings released: EPS: ₫429 (vs ₫436 in 3Q 2024)Third quarter 2025 results: EPS: ₫429. Revenue: ₫573.6b (up 5.3% from 3Q 2024). Net income: ₫76.9b (up 6.2% from 3Q 2024). Profit margin: 13% (in line with 3Q 2024). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia.Upcoming Dividend • Jun 02Upcoming dividend of ₫500 per shareEligible shareholders must have bought the stock before 09 June 2025. Payment date: 09 July 2025. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Vietnamese dividend payers (8.0%). Lower than average of industry peers (5.6%).お知らせ • May 22Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 64.81% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd. and others for VND 5.7 trillion.Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 64.81% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd. and others for VND 5.7 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement.Reported Earnings • Apr 19First quarter 2025 earnings released: EPS: ₫448 (vs ₫371 in 1Q 2024)First quarter 2025 results: EPS: ₫448 (up from ₫371 in 1Q 2024). Revenue: ₫594.1b (up 21% from 1Q 2024). Net income: ₫74.5b (up 42% from 1Q 2024). Profit margin: 13% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.New Risk • Mar 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Vietnamese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Mar 05Imexpharm Corporation, Annual General Meeting, Apr 25, 2025Imexpharm Corporation, Annual General Meeting, Apr 25, 2025.Reported Earnings • Jan 24Full year 2024 earnings released: EPS: ₫1,932 (vs ₫1,653 in FY 2023)Full year 2024 results: EPS: ₫1,932 (up from ₫1,653 in FY 2023). Revenue: ₫2.21t (up 11% from FY 2023). Net income: ₫320.9b (up 26% from FY 2023). Profit margin: 15% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 29Imexpharm Corporation Appoints Sung Min Woo as Chairperson of the Nomination and Compensation Committee Under the Board of DirectorsImexpharm Corporation announced the Board of Directors' Decision No. 08/2024/QÐ-HÐQT-IMP dated November 27, 2024, regarding the appointment of Mr. Sung Min Woo, Chairperson of the Board of Directors, as the Chairperson of the Nomination and Compensation Committee under the Board of Directors.Reported Earnings • Oct 22Third quarter 2024 earnings released: EPS: ₫436 (vs ₫404 in 3Q 2023)Third quarter 2024 results: EPS: ₫436 (up from ₫404 in 3Q 2023). Revenue: ₫544.7b (up 17% from 3Q 2023). Net income: ₫72.4b (up 3.9% from 3Q 2023). Profit margin: 13% (down from 15% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 10% per year.New Risk • Sep 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Vietnamese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Price Target Changed • Aug 23Price target increased by 9.2% to ₫78,485Up from ₫71,861, the current price target is an average from 3 analysts. New target price is 8.1% below last closing price of ₫85,400. Stock is up 46% over the past year. The company is forecast to post earnings per share of ₫4,012 for next year compared to ₫3,307 last year.Reported Earnings • Jul 23Second quarter 2024 earnings released: EPS: ₫794 (vs ₫851 in 2Q 2023)Second quarter 2024 results: EPS: ₫794 (down from ₫851 in 2Q 2023). Revenue: ₫517.2b (up 18% from 2Q 2023). Net income: ₫65.9b (down 4.8% from 2Q 2023). Profit margin: 13% (down from 16% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 9.4% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 10% per year.Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₫81,600, the stock trades at a trailing P/E ratio of 26.1x. Average forward P/E is 19x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₫73,716 per share.Upcoming Dividend • Jul 05Upcoming dividend of ₫1,000 per shareEligible shareholders must have bought the stock before 11 July 2024. Payment date: 23 July 2024. Payout ratio is a comfortable 27% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Vietnamese dividend payers (8.3%). Lower than average of industry peers (3.4%).お知らせ • Jul 04Imexpharm Corporation Announces Dividend for the Year 2023, Payable on July 23, 2024Imexpharm Corporation announced Dividend Payout ratio 10% share based on par value (1 share will receive 1,000 VND) for the year 2023. Payment time is July 23, 2024. Ex-right date: July 11, 2024. Record date: July 12, 2024.Reported Earnings • Apr 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ₫491.1b (up 2.5% from 1Q 2023). Net income: ₫61.9b (up 14% from 1Q 2023). Profit margin: 13% (up from 11% in 1Q 2023).お知らせ • Mar 27Imexpharm Corporation, Annual General Meeting, Apr 26, 2024Imexpharm Corporation, Annual General Meeting, Apr 26, 2024, at 07:45 SE Asia Standard Time. Location: 5th Floor. Hilton Saigon Hotel, No. 11 Me Unh Square, Ben Nghe Ward, District 1, Ho Chi Minh City VietnamReported Earnings • Jan 21Full year 2023 earnings released: EPS: ₫3,637 (vs ₫2,810 in FY 2022)Full year 2023 results: EPS: ₫3,637 (up from ₫2,810 in FY 2022). Revenue: ₫1.99t (up 21% from FY 2022). Net income: ₫299.6b (up 52% from FY 2022). Profit margin: 15% (up from 12% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • Dec 20Imexpharm Corporation Approves Election of Hoang Duc Hung as an Independent Member of the Board of DirectorsImexpharm Corporation announced that at the General Meeting of Shareholders held on December 19, 2023, approved election of Mr. Hoang Duc Hung as an independent member of the Board of Directors of the Company for the term 2023-2027. Year of birth: 1973, Literacy: Postgraduate. Professional level: Master of International Finance (Oxford Brookes), CIA (IIA), FCCA, FCPA Aust, VACPA. Nationality: Vietnamese. Employment history: From 11/1994 to 06/2014: Audit Director, Leadership of Advisory Services Division, Leadership of the Government and Public Sector Clients Division, Ernst & Young (EY) Vietnam Limited. From 07/2014 to 09/2016: International Consultant - World Bank, supporting the Ministry of Finance in building the Internal audit framework in Vietnam. From 10/2016 to 11/2020: Deputy General Director - PwC Vietnam Limited. From 12/2020 to present: Chairman of the BOD - of CGS Vietnam Governance Consultancy Joint Stock Company; Board Member - Gentis Testing Service Joint Stock Company. From 09/2022 to present: Vice President, Executive Committee Member of Vietnam Independent Directors Association; President of Institute of Internal Auditors Vietnam - IIA Vietnam Chapter. Current positions at other Organizations: President of Institute of Internal Auditors Vietnam - IIA Vietnam Chapter. Vice President, Executive Committee Member of Vietnam Independent Directors Association. Chairman of CGS Vietnam Governance Consultancy Joint Stock Company. Members of BOD of Gentis Testing Service Joint Stock Company. Independent BOD Member of No Va Land Investment Group Corporation.Reported Earnings • Oct 21Third quarter 2023 earnings released: EPS: ₫889 (vs ₫817 in 3Q 2022)Third quarter 2023 results: EPS: ₫889 (up from ₫817 in 3Q 2022). Revenue: ₫466.9b (up 12% from 3Q 2022). Net income: ₫69.7b (up 25% from 3Q 2022). Profit margin: 15% (up from 13% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 11% per year and the company’s share price has also increased by 11% per year.Upcoming Dividend • Sep 28Upcoming dividend of ₫1,000 per share at 1.5% yieldEligible shareholders must have bought the stock before 05 October 2023. Payment date: 20 October 2023. Trailing yield: 1.5%. Lower than top quartile of Vietnamese dividend payers (8.8%). Lower than average of industry peers (3.2%).お知らせ • Sep 19Imexpharm Corporation Announces Dividend, Payable on October 20, 2023Imexpharm Corporation announced Dividend Payout ratio 10% share based on par value (1 share will receive 1,000 VND). Payment time is October 20, 2023.Upcoming Dividend • Aug 31Upcoming dividend of ₫1,000 per share at 1.5% yieldEligible shareholders must have bought the stock before 07 September 2023. Payment date: 06 October 2023. Trailing yield: 1.5%. Lower than top quartile of Vietnamese dividend payers (8.6%). Lower than average of industry peers (3.2%).Price Target Changed • Aug 17Price target increased by 14% to ₫84,000Up from ₫73,633, the current price target is provided by 1 analyst. New target price is 20% above last closing price of ₫69,800. Stock is up 10% over the past year. The company is forecast to post earnings per share of ₫4,858 for next year compared to ₫2,951 last year.Reported Earnings • Jul 20Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: ₫439.7b (up 24% from 2Q 2022). Net income: ₫79.7b (up 66% from 2Q 2022). Profit margin: 18% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia.お知らせ • May 07Imexpharm Corporation Appoints Chun Chaerhan as Chairperson of the Board of DirectorsImexpharm Corporation at its board meeting held on April 28, 2023, approved the election of Ms. Chun Chaerhan to hold the position of Chairperson of the Board of Directors of the company. The Chairperson of the Board of Directors is responsible for performing her obligations and powers in accordance with the Company's Charter, the Internal Regulations on Governance, the Operating Rules of the Board of Directors, and the provisions of law.Reported Earnings • Mar 28Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: ₫2,951 (up from ₫2,603 in FY 2021). Revenue: ₫1.64t (up 30% from FY 2021). Net income: ₫196.7b (up 13% from FY 2021). Profit margin: 12% (down from 14% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.4%. Earnings per share (EPS) also surpassed analyst estimates by 1.5%. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jan 19Full year 2022 earnings released: EPS: ₫3,495 (vs ₫2,600 in FY 2021)Full year 2022 results: EPS: ₫3,495 (up from ₫2,600 in FY 2021). Revenue: ₫1.64t (up 30% from FY 2021). Net income: ₫234.0b (up 35% from FY 2021). Profit margin: 14% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 14% per year.Price Target Changed • Jan 04Price target decreased to ₫66,600Down from ₫73,633, the current price target is an average from 2 analysts. New target price is 11% above last closing price of ₫60,200. Stock is down 21% over the past year. The company is forecast to post earnings per share of ₫3,444 for next year compared to ₫2,600 last year.Valuation Update With 7 Day Price Move • Dec 02Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₫62,500, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 63% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₫56,442 per share.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Hung Truong was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 21Third quarter 2022 earnings released: EPS: ₫858 (vs ₫413 in 3Q 2021)Third quarter 2022 results: EPS: ₫858 (up from ₫413 in 3Q 2021). Revenue: ₫417.8b (up 63% from 3Q 2021). Net income: ₫55.8b (up 78% from 3Q 2021). Profit margin: 13% (up from 12% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 25Imexpharm Corporation announced that it has received funding from SK Group Ltd.Imexpharm Corporation announced that it has received a round of funding from SK Group Ltd. on August 25, 2022.Reported Earnings • Jul 23Second quarter 2022 earnings released: EPS: ₫615 (vs ₫684 in 2Q 2021)Second quarter 2022 results: EPS: ₫615. Revenue: ₫354.5b (up 12% from 2Q 2021). Net income: ₫46.6b (up 2.3% from 2Q 2021). Profit margin: 13% (down from 14% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 25%, compared to a 24% growth forecast for the industry in Vietnam.Price Target Changed • Jul 14Price target increased to ₫79,000Up from ₫73,633, the current price target is an average from 2 analysts. New target price is 27% above last closing price of ₫62,000. Stock is down 15% over the past year. The company is forecast to post earnings per share of ₫3,069 for next year compared to ₫2,600 last year.お知らせ • Jun 01Imexpharm Corporation Announces Personnel ChangeOn May 25, 2022, Imexpharm Corporation announces the appointment of Mrs. Han Thi Khanh Vinh – member of BOD as Head of Internal Audit Subcommittee and Risk Management Department to replace Mr. Tran Anh Tuan from May 24, 2022.Upcoming Dividend • May 18Upcoming dividend of ₫1,500 per shareEligible shareholders must have bought the stock before 25 May 2022. Payment date: 24 June 2022. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Vietnamese dividend payers (7.3%). Lower than average of industry peers (3.6%).お知らせ • May 14Imexpharm Corporation Announces Cash Dividend for 2021, Payable on June 24, 2022Imexpharm Corporation announced to pay cash dividend for 2021. Exercise ratio: 15.0% (VND 1,500/share). Payment date: June 24, 2022. Ex-right date: May 25, 2022. Record date: May 26, 2022.Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 3 experienced directors. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Hung Truong was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Mar 13Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: EPS: ₫2,600 (down from ₫2,773 in FY 2020). Revenue: ₫1.27t (down 7.5% from FY 2020). Net income: ₫173.4b (down 3.5% from FY 2020). Profit margin: 14% (in line with FY 2020). Revenue missed analyst estimates by 9.2%. Earnings per share (EPS) also missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 19%, compared to a 19% growth forecast for the pharmaceuticals industry in Vietnam. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Oct 21Third quarter 2021 earnings released: EPS ₫413 (vs ₫478 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₫256.2b (down 12% from 3Q 2020). Net income: ₫31.3b (down 39% from 3Q 2020). Profit margin: 12% (down from 18% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.Price Target Changed • Aug 10Price target increased to ₫75,300Up from ₫68,400, the current price target is an average from 3 analysts. New target price is 5.5% above last closing price of ₫71,400. Stock is up 63% over the past year.Reported Earnings • Jul 23Second quarter 2021 earnings released: EPS ₫651 (vs ₫1,180 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₫317.4b (up 9.9% from 2Q 2020). Net income: ₫49.3b (up 36% from 2Q 2020). Profit margin: 16% (up from 13% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 22% per year.Upcoming Dividend • Jun 16Upcoming dividend of ₫1,500 per shareEligible shareholders must have bought the stock before 23 June 2021. Payment date: 16 July 2021. Trailing yield: 2.0%. Lower than top quartile of Vietnamese dividend payers (7.5%). Lower than average of industry peers (3.8%).Reported Earnings • Apr 24First quarter 2021 earnings released: EPS ₫615 (vs ₫564 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: ₫296.4b (down 2.4% from 1Q 2020). Net income: ₫41.0b (up 13% from 1Q 2020). Profit margin: 14% (up from 12% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 19% per year and the company’s share price has also increased by 19% per year.Reported Earnings • Mar 20Full year 2020 earnings released: EPS ₫2,773 (vs ₫2,225 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₫1.37t (down 2.4% from FY 2019). Net income: ₫179.7b (up 26% from FY 2019). Profit margin: 13% (up from 10% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 20% per year.Is New 90 Day High Low • Feb 18New 90-day high: ₫60,600The company is up 17% from its price of ₫52,000 on 20 November 2020. The Vietnamese market is also up 17% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫26,735 per share.Analyst Estimate Surprise Post Earnings • Jan 23Revenue and earnings miss expectationsRevenue missed analyst estimates by 3.2%. Earnings per share (EPS) also missed analyst estimates by 4.4%. Over the next year, revenue is forecast to grow 39%, compared to a 247% growth forecast for the Pharmaceuticals industry in Vietnam.Reported Earnings • Jan 20Full year 2020 earnings released: EPS ₫2,773The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₫1.37t (down 2.4% from FY 2019). Net income: ₫209.7b (up 47% from FY 2019). Profit margin: 15% (up from 10% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Jan 04New 90-day high: ₫58,000The company is up 21% from its price of ₫48,000 on 06 October 2020. The Vietnamese market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫23,764 per share.Price Target Changed • Dec 23Price target raised to ₫57,910Up from ₫52,663, the current price target is an average from 2 analysts. The new target price is close to the current share price of ₫56,000. As of last close, the stock is up 49% over the past year.Is New 90 Day High Low • Dec 14New 90-day high: ₫56,800The company is up 15% from its price of ₫49,500 on 15 September 2020. The Vietnamese market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫20,200 per share.Is New 90 Day High Low • Nov 25New 90-day high: ₫54,900The company is up 14% from its price of ₫48,100 on 27 August 2020. The Vietnamese market is also up 14% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫16,865 per share.Is New 90 Day High Low • Nov 02New 90-day high: ₫49,550The company is up 11% from its price of ₫44,500 on 04 August 2020. The Vietnamese market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫16,865 per share.Reported Earnings • Oct 21Third quarter earnings releasedOver the last 12 months the company has reported total profits of ₫180.0b, up 32% from the prior year. Total revenue was ₫1.40t over the last 12 months, up 11% from the prior year.業績と収益の成長予測HOSE:IMP - アナリストの将来予測と過去の財務データ ( )VND Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20272,881,000428,000N/A354,000112/31/20262,659,000394,000N/A431,00013/31/20262,393,233311,122277,856292,537N/A12/31/20252,441,085304,38927,29254,171N/A9/30/20252,452,365326,405-88,020-34,768N/A6/30/20252,423,552321,92224,20774,631N/A3/31/20252,308,077298,178-1,419102,548N/A1/1/20252,205,120275,862119,497216,268N/A9/30/20242,161,215239,307158,658239,210N/A6/30/20242,083,396236,60317,048100,709N/A3/31/20242,005,866255,424-86,744-26,284N/A1/1/20241,994,037277,778-103,064-39,535N/A9/30/20231,943,044262,780-103,565-40,471N/A6/30/20231,893,973248,8648,49096,011N/A3/31/20231,808,733212,500158,215259,703N/A12/31/20221,643,707183,844279,250378,603N/A9/30/20221,483,063193,294297,677395,679N/A6/30/20221,321,432168,823270,162341,411N/A3/31/20221,284,405176,146223,927270,927N/A12/31/20211,266,597173,513182,024234,881N/A9/30/20211,357,095173,320171,377251,569N/A6/30/20211,390,894192,89465,544158,384N/A3/31/20211,362,172184,24235,719127,814N/A12/31/20201,369,422179,658-16,53173,153N/A9/30/20201,398,480164,014-56,80730,791N/A6/30/20201,436,011154,63649,115141,807N/A3/31/20201,432,983145,35443,102148,864N/A12/31/20191,402,454142,900N/A66,590N/A9/30/20191,261,051131,865N/A93,724N/A6/30/20191,230,077125,694N/A95,652N/A3/31/20191,204,780124,885N/A65,352N/A12/31/20181,184,818122,041N/A132,094N/A9/30/20181,224,760112,394N/A99,254N/A6/30/20181,178,882106,176N/A-12,288N/A3/31/20181,194,327109,745N/A105,208N/A12/31/20171,165,456103,277N/A97,213N/A9/30/20171,116,855110,222N/A16,911N/A6/30/20171,081,387104,160N/A89,001N/A3/31/20171,041,96790,389N/A46,888N/A12/31/20161,010,34688,009N/A84,651N/A9/30/2016979,58775,696N/A153,940N/A6/30/2016948,20870,215N/A132,462N/A3/31/2016941,85778,639N/A59,986N/A12/31/2015964,31981,760N/A44,799N/A9/30/2015935,08581,196N/A-11,198N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: IMPの予測収益成長率 (年間17.2% ) は 貯蓄率 ( 3.2% ) を上回っています。収益対市場: IMPの収益 ( 17.2% ) VN市場 ( 19.8% ) よりも低い成長が予測されています。高成長収益: IMPの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: IMPの収益 ( 10.4% ) VN市場 ( 15.5% ) よりも低い成長が予測されています。高い収益成長: IMPの収益 ( 10.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: IMPの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/18 07:13終値2026/07/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Imexpharm Corporation 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関null nullFPT SecuritiesQuan CaoViet Dragon Securities Corporation
Price Target Changed • Aug 23Price target increased by 9.2% to ₫78,485Up from ₫71,861, the current price target is an average from 3 analysts. New target price is 8.1% below last closing price of ₫85,400. Stock is up 46% over the past year. The company is forecast to post earnings per share of ₫4,012 for next year compared to ₫3,307 last year.
Price Target Changed • Aug 17Price target increased by 14% to ₫84,000Up from ₫73,633, the current price target is provided by 1 analyst. New target price is 20% above last closing price of ₫69,800. Stock is up 10% over the past year. The company is forecast to post earnings per share of ₫4,858 for next year compared to ₫2,951 last year.
Price Target Changed • Jan 04Price target decreased to ₫66,600Down from ₫73,633, the current price target is an average from 2 analysts. New target price is 11% above last closing price of ₫60,200. Stock is down 21% over the past year. The company is forecast to post earnings per share of ₫3,444 for next year compared to ₫2,600 last year.
Price Target Changed • Jul 14Price target increased to ₫79,000Up from ₫73,633, the current price target is an average from 2 analysts. New target price is 27% above last closing price of ₫62,000. Stock is down 15% over the past year. The company is forecast to post earnings per share of ₫3,069 for next year compared to ₫2,600 last year.
Price Target Changed • Aug 10Price target increased to ₫75,300Up from ₫68,400, the current price target is an average from 3 analysts. New target price is 5.5% above last closing price of ₫71,400. Stock is up 63% over the past year.
Price Target Changed • Dec 23Price target raised to ₫57,910Up from ₫52,663, the current price target is an average from 2 analysts. The new target price is close to the current share price of ₫56,000. As of last close, the stock is up 49% over the past year.
Upcoming Dividend • Jul 06Upcoming dividend of ₫600 per shareEligible shareholders must have bought the stock before 13 July 2026. Payment date: 21 July 2026. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Vietnamese dividend payers (8.1%). Lower than average of industry peers (3.7%).
お知らせ • Jul 03Imexpharm Corporation Announces Cash Dividend for the Year 2025, Payable on July 21, 2026Imexpharm Corporation announced the cash dividend of 6% per share VND 600 for each share for the year 2025, payable on July 21, 2026. Record date is on July 14, 2026.
お知らせ • Apr 30Livzon Pharmaceutical Group Inc. (SZSE:000513) acquired 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion.Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 77.94% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6.9 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. On December 29, 2025, the parties signed Amendment Agreement to Framework Agreement agreeing to increase the maximum number of shares to be acquired through this proposed public tender offer to 120,059,970 shares, 77.94% stake, in accordance with Imexpharm Corporation’s foreign ownership cap requirements, and the Company will pay a maximum of VND 6,891,442,278,000. As of March 6, 2026 Livzon Pharmaceutical Group has officially received approval from the State Securities Commission of Vietnam. This allows them to proceed with a voluntary public tender offer for IMP shares. The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The number of shares intended to be sold by the Target Company’s shareholders does not reach the minimum threshold of 99,839,990 shares, representing 64.81% of the Target Company’s charter capital. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement. The transaction has been approved by the board of directors of Livzon Pharmaceutical Group Inc. Ernst & Young Vietnam Limited acted as due diligence provider to SK Investment Vina III Pte Ltd. Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion on April 29, 2026. Shareholders of Livzon Pharmaceutical Group Inc. have reached the minimum threshold of 99,839,990 shares, representing 64.81% of Imexpharm Corporation.
Reported Earnings • Mar 28Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: EPS: ₫1,976 (up from ₫1,791 in FY 2024). Revenue: ₫2.44t (up 11% from FY 2024). Net income: ₫304.4b (up 10% from FY 2024). Profit margin: 13% (in line with FY 2024). Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 09Imexpharm Corporation, Annual General Meeting, Apr 22, 2026Imexpharm Corporation, Annual General Meeting, Apr 22, 2026.
Reported Earnings • Jan 22Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: EPS: ₫1,976 (up from ₫1,932 in FY 2024). Revenue: ₫2.44t (up 11% from FY 2024). Net income: ₫304.4b (up 2.3% from FY 2024). Profit margin: 13% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Oct 23Third quarter 2025 earnings released: EPS: ₫429 (vs ₫436 in 3Q 2024)Third quarter 2025 results: EPS: ₫429. Revenue: ₫573.6b (up 5.3% from 3Q 2024). Net income: ₫76.9b (up 6.2% from 3Q 2024). Profit margin: 13% (in line with 3Q 2024). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia.
Upcoming Dividend • Jun 02Upcoming dividend of ₫500 per shareEligible shareholders must have bought the stock before 09 June 2025. Payment date: 09 July 2025. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Vietnamese dividend payers (8.0%). Lower than average of industry peers (5.6%).
お知らせ • May 22Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 64.81% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd. and others for VND 5.7 trillion.Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 64.81% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd. and others for VND 5.7 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement.
Reported Earnings • Apr 19First quarter 2025 earnings released: EPS: ₫448 (vs ₫371 in 1Q 2024)First quarter 2025 results: EPS: ₫448 (up from ₫371 in 1Q 2024). Revenue: ₫594.1b (up 21% from 1Q 2024). Net income: ₫74.5b (up 42% from 1Q 2024). Profit margin: 13% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
New Risk • Mar 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Vietnamese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Mar 05Imexpharm Corporation, Annual General Meeting, Apr 25, 2025Imexpharm Corporation, Annual General Meeting, Apr 25, 2025.
Reported Earnings • Jan 24Full year 2024 earnings released: EPS: ₫1,932 (vs ₫1,653 in FY 2023)Full year 2024 results: EPS: ₫1,932 (up from ₫1,653 in FY 2023). Revenue: ₫2.21t (up 11% from FY 2023). Net income: ₫320.9b (up 26% from FY 2023). Profit margin: 15% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 29Imexpharm Corporation Appoints Sung Min Woo as Chairperson of the Nomination and Compensation Committee Under the Board of DirectorsImexpharm Corporation announced the Board of Directors' Decision No. 08/2024/QÐ-HÐQT-IMP dated November 27, 2024, regarding the appointment of Mr. Sung Min Woo, Chairperson of the Board of Directors, as the Chairperson of the Nomination and Compensation Committee under the Board of Directors.
Reported Earnings • Oct 22Third quarter 2024 earnings released: EPS: ₫436 (vs ₫404 in 3Q 2023)Third quarter 2024 results: EPS: ₫436 (up from ₫404 in 3Q 2023). Revenue: ₫544.7b (up 17% from 3Q 2023). Net income: ₫72.4b (up 3.9% from 3Q 2023). Profit margin: 13% (down from 15% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 10% per year.
New Risk • Sep 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Vietnamese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Price Target Changed • Aug 23Price target increased by 9.2% to ₫78,485Up from ₫71,861, the current price target is an average from 3 analysts. New target price is 8.1% below last closing price of ₫85,400. Stock is up 46% over the past year. The company is forecast to post earnings per share of ₫4,012 for next year compared to ₫3,307 last year.
Reported Earnings • Jul 23Second quarter 2024 earnings released: EPS: ₫794 (vs ₫851 in 2Q 2023)Second quarter 2024 results: EPS: ₫794 (down from ₫851 in 2Q 2023). Revenue: ₫517.2b (up 18% from 2Q 2023). Net income: ₫65.9b (down 4.8% from 2Q 2023). Profit margin: 13% (down from 16% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 9.4% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 10% per year.
Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₫81,600, the stock trades at a trailing P/E ratio of 26.1x. Average forward P/E is 19x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₫73,716 per share.
Upcoming Dividend • Jul 05Upcoming dividend of ₫1,000 per shareEligible shareholders must have bought the stock before 11 July 2024. Payment date: 23 July 2024. Payout ratio is a comfortable 27% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Vietnamese dividend payers (8.3%). Lower than average of industry peers (3.4%).
お知らせ • Jul 04Imexpharm Corporation Announces Dividend for the Year 2023, Payable on July 23, 2024Imexpharm Corporation announced Dividend Payout ratio 10% share based on par value (1 share will receive 1,000 VND) for the year 2023. Payment time is July 23, 2024. Ex-right date: July 11, 2024. Record date: July 12, 2024.
Reported Earnings • Apr 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ₫491.1b (up 2.5% from 1Q 2023). Net income: ₫61.9b (up 14% from 1Q 2023). Profit margin: 13% (up from 11% in 1Q 2023).
お知らせ • Mar 27Imexpharm Corporation, Annual General Meeting, Apr 26, 2024Imexpharm Corporation, Annual General Meeting, Apr 26, 2024, at 07:45 SE Asia Standard Time. Location: 5th Floor. Hilton Saigon Hotel, No. 11 Me Unh Square, Ben Nghe Ward, District 1, Ho Chi Minh City Vietnam
Reported Earnings • Jan 21Full year 2023 earnings released: EPS: ₫3,637 (vs ₫2,810 in FY 2022)Full year 2023 results: EPS: ₫3,637 (up from ₫2,810 in FY 2022). Revenue: ₫1.99t (up 21% from FY 2022). Net income: ₫299.6b (up 52% from FY 2022). Profit margin: 15% (up from 12% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • Dec 20Imexpharm Corporation Approves Election of Hoang Duc Hung as an Independent Member of the Board of DirectorsImexpharm Corporation announced that at the General Meeting of Shareholders held on December 19, 2023, approved election of Mr. Hoang Duc Hung as an independent member of the Board of Directors of the Company for the term 2023-2027. Year of birth: 1973, Literacy: Postgraduate. Professional level: Master of International Finance (Oxford Brookes), CIA (IIA), FCCA, FCPA Aust, VACPA. Nationality: Vietnamese. Employment history: From 11/1994 to 06/2014: Audit Director, Leadership of Advisory Services Division, Leadership of the Government and Public Sector Clients Division, Ernst & Young (EY) Vietnam Limited. From 07/2014 to 09/2016: International Consultant - World Bank, supporting the Ministry of Finance in building the Internal audit framework in Vietnam. From 10/2016 to 11/2020: Deputy General Director - PwC Vietnam Limited. From 12/2020 to present: Chairman of the BOD - of CGS Vietnam Governance Consultancy Joint Stock Company; Board Member - Gentis Testing Service Joint Stock Company. From 09/2022 to present: Vice President, Executive Committee Member of Vietnam Independent Directors Association; President of Institute of Internal Auditors Vietnam - IIA Vietnam Chapter. Current positions at other Organizations: President of Institute of Internal Auditors Vietnam - IIA Vietnam Chapter. Vice President, Executive Committee Member of Vietnam Independent Directors Association. Chairman of CGS Vietnam Governance Consultancy Joint Stock Company. Members of BOD of Gentis Testing Service Joint Stock Company. Independent BOD Member of No Va Land Investment Group Corporation.
Reported Earnings • Oct 21Third quarter 2023 earnings released: EPS: ₫889 (vs ₫817 in 3Q 2022)Third quarter 2023 results: EPS: ₫889 (up from ₫817 in 3Q 2022). Revenue: ₫466.9b (up 12% from 3Q 2022). Net income: ₫69.7b (up 25% from 3Q 2022). Profit margin: 15% (up from 13% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 11% per year and the company’s share price has also increased by 11% per year.
Upcoming Dividend • Sep 28Upcoming dividend of ₫1,000 per share at 1.5% yieldEligible shareholders must have bought the stock before 05 October 2023. Payment date: 20 October 2023. Trailing yield: 1.5%. Lower than top quartile of Vietnamese dividend payers (8.8%). Lower than average of industry peers (3.2%).
お知らせ • Sep 19Imexpharm Corporation Announces Dividend, Payable on October 20, 2023Imexpharm Corporation announced Dividend Payout ratio 10% share based on par value (1 share will receive 1,000 VND). Payment time is October 20, 2023.
Upcoming Dividend • Aug 31Upcoming dividend of ₫1,000 per share at 1.5% yieldEligible shareholders must have bought the stock before 07 September 2023. Payment date: 06 October 2023. Trailing yield: 1.5%. Lower than top quartile of Vietnamese dividend payers (8.6%). Lower than average of industry peers (3.2%).
Price Target Changed • Aug 17Price target increased by 14% to ₫84,000Up from ₫73,633, the current price target is provided by 1 analyst. New target price is 20% above last closing price of ₫69,800. Stock is up 10% over the past year. The company is forecast to post earnings per share of ₫4,858 for next year compared to ₫2,951 last year.
Reported Earnings • Jul 20Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: ₫439.7b (up 24% from 2Q 2022). Net income: ₫79.7b (up 66% from 2Q 2022). Profit margin: 18% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia.
お知らせ • May 07Imexpharm Corporation Appoints Chun Chaerhan as Chairperson of the Board of DirectorsImexpharm Corporation at its board meeting held on April 28, 2023, approved the election of Ms. Chun Chaerhan to hold the position of Chairperson of the Board of Directors of the company. The Chairperson of the Board of Directors is responsible for performing her obligations and powers in accordance with the Company's Charter, the Internal Regulations on Governance, the Operating Rules of the Board of Directors, and the provisions of law.
Reported Earnings • Mar 28Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: ₫2,951 (up from ₫2,603 in FY 2021). Revenue: ₫1.64t (up 30% from FY 2021). Net income: ₫196.7b (up 13% from FY 2021). Profit margin: 12% (down from 14% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.4%. Earnings per share (EPS) also surpassed analyst estimates by 1.5%. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jan 19Full year 2022 earnings released: EPS: ₫3,495 (vs ₫2,600 in FY 2021)Full year 2022 results: EPS: ₫3,495 (up from ₫2,600 in FY 2021). Revenue: ₫1.64t (up 30% from FY 2021). Net income: ₫234.0b (up 35% from FY 2021). Profit margin: 14% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 14% per year.
Price Target Changed • Jan 04Price target decreased to ₫66,600Down from ₫73,633, the current price target is an average from 2 analysts. New target price is 11% above last closing price of ₫60,200. Stock is down 21% over the past year. The company is forecast to post earnings per share of ₫3,444 for next year compared to ₫2,600 last year.
Valuation Update With 7 Day Price Move • Dec 02Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₫62,500, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 63% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₫56,442 per share.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Hung Truong was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 21Third quarter 2022 earnings released: EPS: ₫858 (vs ₫413 in 3Q 2021)Third quarter 2022 results: EPS: ₫858 (up from ₫413 in 3Q 2021). Revenue: ₫417.8b (up 63% from 3Q 2021). Net income: ₫55.8b (up 78% from 3Q 2021). Profit margin: 13% (up from 12% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 25Imexpharm Corporation announced that it has received funding from SK Group Ltd.Imexpharm Corporation announced that it has received a round of funding from SK Group Ltd. on August 25, 2022.
Reported Earnings • Jul 23Second quarter 2022 earnings released: EPS: ₫615 (vs ₫684 in 2Q 2021)Second quarter 2022 results: EPS: ₫615. Revenue: ₫354.5b (up 12% from 2Q 2021). Net income: ₫46.6b (up 2.3% from 2Q 2021). Profit margin: 13% (down from 14% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 25%, compared to a 24% growth forecast for the industry in Vietnam.
Price Target Changed • Jul 14Price target increased to ₫79,000Up from ₫73,633, the current price target is an average from 2 analysts. New target price is 27% above last closing price of ₫62,000. Stock is down 15% over the past year. The company is forecast to post earnings per share of ₫3,069 for next year compared to ₫2,600 last year.
お知らせ • Jun 01Imexpharm Corporation Announces Personnel ChangeOn May 25, 2022, Imexpharm Corporation announces the appointment of Mrs. Han Thi Khanh Vinh – member of BOD as Head of Internal Audit Subcommittee and Risk Management Department to replace Mr. Tran Anh Tuan from May 24, 2022.
Upcoming Dividend • May 18Upcoming dividend of ₫1,500 per shareEligible shareholders must have bought the stock before 25 May 2022. Payment date: 24 June 2022. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Vietnamese dividend payers (7.3%). Lower than average of industry peers (3.6%).
お知らせ • May 14Imexpharm Corporation Announces Cash Dividend for 2021, Payable on June 24, 2022Imexpharm Corporation announced to pay cash dividend for 2021. Exercise ratio: 15.0% (VND 1,500/share). Payment date: June 24, 2022. Ex-right date: May 25, 2022. Record date: May 26, 2022.
Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 3 experienced directors. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Hung Truong was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 13Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: EPS: ₫2,600 (down from ₫2,773 in FY 2020). Revenue: ₫1.27t (down 7.5% from FY 2020). Net income: ₫173.4b (down 3.5% from FY 2020). Profit margin: 14% (in line with FY 2020). Revenue missed analyst estimates by 9.2%. Earnings per share (EPS) also missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 19%, compared to a 19% growth forecast for the pharmaceuticals industry in Vietnam. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Oct 21Third quarter 2021 earnings released: EPS ₫413 (vs ₫478 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₫256.2b (down 12% from 3Q 2020). Net income: ₫31.3b (down 39% from 3Q 2020). Profit margin: 12% (down from 18% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
Price Target Changed • Aug 10Price target increased to ₫75,300Up from ₫68,400, the current price target is an average from 3 analysts. New target price is 5.5% above last closing price of ₫71,400. Stock is up 63% over the past year.
Reported Earnings • Jul 23Second quarter 2021 earnings released: EPS ₫651 (vs ₫1,180 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₫317.4b (up 9.9% from 2Q 2020). Net income: ₫49.3b (up 36% from 2Q 2020). Profit margin: 16% (up from 13% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 22% per year.
Upcoming Dividend • Jun 16Upcoming dividend of ₫1,500 per shareEligible shareholders must have bought the stock before 23 June 2021. Payment date: 16 July 2021. Trailing yield: 2.0%. Lower than top quartile of Vietnamese dividend payers (7.5%). Lower than average of industry peers (3.8%).
Reported Earnings • Apr 24First quarter 2021 earnings released: EPS ₫615 (vs ₫564 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: ₫296.4b (down 2.4% from 1Q 2020). Net income: ₫41.0b (up 13% from 1Q 2020). Profit margin: 14% (up from 12% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 19% per year and the company’s share price has also increased by 19% per year.
Reported Earnings • Mar 20Full year 2020 earnings released: EPS ₫2,773 (vs ₫2,225 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₫1.37t (down 2.4% from FY 2019). Net income: ₫179.7b (up 26% from FY 2019). Profit margin: 13% (up from 10% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 20% per year.
Is New 90 Day High Low • Feb 18New 90-day high: ₫60,600The company is up 17% from its price of ₫52,000 on 20 November 2020. The Vietnamese market is also up 17% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫26,735 per share.
Analyst Estimate Surprise Post Earnings • Jan 23Revenue and earnings miss expectationsRevenue missed analyst estimates by 3.2%. Earnings per share (EPS) also missed analyst estimates by 4.4%. Over the next year, revenue is forecast to grow 39%, compared to a 247% growth forecast for the Pharmaceuticals industry in Vietnam.
Reported Earnings • Jan 20Full year 2020 earnings released: EPS ₫2,773The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₫1.37t (down 2.4% from FY 2019). Net income: ₫209.7b (up 47% from FY 2019). Profit margin: 15% (up from 10% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Jan 04New 90-day high: ₫58,000The company is up 21% from its price of ₫48,000 on 06 October 2020. The Vietnamese market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫23,764 per share.
Price Target Changed • Dec 23Price target raised to ₫57,910Up from ₫52,663, the current price target is an average from 2 analysts. The new target price is close to the current share price of ₫56,000. As of last close, the stock is up 49% over the past year.
Is New 90 Day High Low • Dec 14New 90-day high: ₫56,800The company is up 15% from its price of ₫49,500 on 15 September 2020. The Vietnamese market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫20,200 per share.
Is New 90 Day High Low • Nov 25New 90-day high: ₫54,900The company is up 14% from its price of ₫48,100 on 27 August 2020. The Vietnamese market is also up 14% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫16,865 per share.
Is New 90 Day High Low • Nov 02New 90-day high: ₫49,550The company is up 11% from its price of ₫44,500 on 04 August 2020. The Vietnamese market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫16,865 per share.
Reported Earnings • Oct 21Third quarter earnings releasedOver the last 12 months the company has reported total profits of ₫180.0b, up 32% from the prior year. Total revenue was ₫1.40t over the last 12 months, up 11% from the prior year.